ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • Fibromyalgia and immune deficiency
  • fibromyalgia and inflammatory arthritis
  • fibromyalgia and inflammatory back pain
  • Fibromyalgia and interdisplinary
  • fibromyalgia and laboratory tests
  • Fibromyalgia and mediation
  • Fibromyalgia and medication
  • fibromyalgia and memory
  • fibromyalgia and mental health
  • fibromyalgia and meta-analysis
  • Fibromyalgia and naltrexone
  • Fibromyalgia and neurologic involvement
  • fibromyalgia and nurse practitioners
  • fibromyalgia and observation
  • Fibromyalgia and opioids
  • fibromyalgia and outcome measures
  • fibromyalgia and oxytocin
  • fibromyalgia and pain
  • fibromyalgia and pain management
  • fibromyalgia and painDETECT
  • fibromyalgia and patient outcomes
  • fibromyalgia and patient-reported outcome measures
  • Fibromyalgia and pediatric rheumatology
  • fibromyalgia and physical activity
  • fibromyalgia and physical therapy
  • Fibromyalgia and polymorphism
  • Fibromyalgia and population studies
  • fibromyalgia and positive affect
  • Fibromyalgia and practice guidelines
  • fibromyalgia and psoriatic arthritis
  • Fibromyalgia and psychological status
  • Fibromyalgia and quality of life
  • Fibromyalgia and questionnaires
  • fibromyalgia and randomized trials
  • Fibromyalgia and registry
  • fibromyalgia and rehabilitation
  • Fibromyalgia and rheumatic disease
  • fibromyalgia and rheumatoid arthritis (RA)
  • fibromyalgia and Rheumatologic Conditions
  • fibromyalgia and self-management
  • Fibromyalgia and severity
  • Fibromyalgia and skin
  • Fibromyalgia and sleep
  • Fibromyalgia and sleep apnea
  • Fibromyalgia and sleep disorders
  • fibromyalgia and small fiber neuropathy
  • fibromyalgia and spondylarthritis
  • fibromyalgia and spondylarthropathy
  • fibromyalgia and stress
  • fibromyalgia and Support and Education Groups
  • fibromyalgia and systemic lupus erythematosus (SLE)
  • fibromyalgia and therapeutic targeting
  • fibromyalgia and tobacco use
  • Fibromyalgia and treatment
  • Fibromyalgia and ultrasound
  • Fibromyalgia and vaccines
  • Fibromyalgia and viruses
  • fibromyalgia and visual analogue scale
  • fibromyalgia and vitamins
  • Fibromyalgia and x-ray
  • FibroScan
  • Fibrosing syndromes
  • fibrosis
  • fibrosis and CD4+CTL
  • fibrosis and cutaneous manifestations
  • fibrosis and heart block
  • fibrosis and inflammation
  • fibrosis and interferons
  • fibrosis and lupus nephritis
  • fibrosis and mast cells
  • fibrosis and rheumatoid arthritis (RA)
  • fibrosis and salivary gland
  • fibrosis and Science
  • fibrosis and scleroderma
  • fibrosis and skin fibrosis
  • fibrosis and SLAMF7
  • fibrosis and systemic sclerosis
  • fibrosis and transforming growth factor
  • fibrosis and vasculopaty
  • filgotinib
  • first in human
  • flare
  • flare and anti-TNF therapy
  • flare and biomarkers
  • flare and patient questionnaires
  • flare-up
  • Fli1
  • flow cytometry
  • flow cytometry and 18FDG PET/CT scan
  • flow cytometry and anti-TNF therapy
  • flow cytometry and genetics
  • flow cytometry and glomerulonephritis
  • flow cytometry and immune response
  • flow cytometry and laboratory tests
  • flow cytometry and monocytes
  • flow cytometry and mouse model
  • flow cytometry and mTor
  • flow cytometry and osteoarthritis
  • flow cytometry and pathogenesis
  • flow cytometry and remission
  • flow cytometry and rheumatoid arthritis (RA)
  • flow cytometry and systemic lupus erythematosus (SLE)
  • flow cytometry and therapeutic targeting
  • flow cytometry and toll-like receptors
  • Fluorescence imaging
  • FM
  • FMF
  • FMRI
  • fMRI and Disease Activity
  • fMRI and fatigue
  • fMRI and fibromyalgia
  • fMRI and systemic lupus erythematosus (SLE)
  • focus group
  • Follicular Helper T cell and Reactive oxygen species
  • follow-up
  • Follow-up and biologic drugs
  • foot
  • foot and osteoarthritis
  • foot and pain
  • Foot and psoriatic arthritis
  • foot care
  • Foot care and synovitis
  • foot disorders
  • Foot disorders and juvenile spondylarthropathy
  • foot disorders and meta-analysis
  • foot disorders and muscle strength
  • foot disorders and osteoarthritis
  • Foot disorders and pain
  • foot wear
  • foot wear and gait
  • Foot wear and gout
  • foot wear and osteoarthritis
  • forced vital capacity and systemic sclerosis
  • Fosl-2 and systemic sclerosis
  • foxo
  • FOXO1 and tumor necrosis factor (TNF)
  • Foxp3 and Treg cell
  • Fra-2
  • Fracture
  • Fracture risk
  • fracture risk and fractures
  • Fracture risk and nutrition
  • fracture risk and osteoarthritis
  • fracture risk and osteoporosis
  • fracture risk and race/ethnicity
  • fracture risk and rheumatoid arthritis (RA)
  • fracture risk and spine involvement
  • fracture risk and trainee
  • fracture risk and tumor necrosis factor (TNF)
  • fracture risk and women's health
  • fractures
  • fractures and Bone
  • fractures and DXA
  • fractures and hematopoietic stem cells
  • fractures and immunodeficiency
  • fractures and incidence rate
  • fractures and juvenile SLE
  • fractures and Medicare
  • Fractures and myositis
  • fractures and obesity
  • fractures and observation
  • fractures and osteonecrosis of the jaw
  • fractures and osteoporosis
  • Fractures and physical function
  • fractures and radiography
  • Fractures and rheumatoid arthritis (RA)
  • fractures and risk assessment
  • fractures and steroids
  • fractures and trauma
  • fractures and tumor necrosis factor (TNF)
  • frail
  • frail and claims
  • frail and sarcopenia
  • frailty
  • Framingham Cardiovascular risk score
  • Free Interleukin-18 (IL-18)
  • Functional Genomics
  • Functional Genomics and autoimmunity
  • Functional Index
  • functional status
  • functional status and giant cell arteritis
  • functional status and hepatitis
  • functional status and hypertension
  • functional status and inflammation
  • functional status and juvenile idiopathic arthritis (JIA)
  • functional status and myositis
  • functional status and osteoarthritis
  • functional status and outcome measures
  • functional status and outcomes
  • functional status and pain
  • functional status and physical activity
  • Functional status and prognostic factors
  • functional status and psoriatic arthritis
  • functional status and qualitative
  • functional status and quality of life
  • functional status and radiography
  • functional status and remission
  • functional status and rheumatoid arthritis
  • functional status and rheumatoid arthritis (RA)
  • functional status and spondylarthritis
  • First |
  • « Previous Page
  • 18
  • 19
  • 20
  • 21
  • 22
  • [23]
  • 24
  • 25
  • 26
  • 27
  • 28
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology